Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

590 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical Outcomes of S-1 Monotherapy and Modified FOLFIRINOX Therapy after Gemcitabine plus Nab-paclitaxel Therapy in Unresectable Pancreatic Cancer.
Hino K, Nishina T, Numata Y, Asagi A, Inoue T, Yoshimatsu M, Sakaguchi C, Nakasya A, Nishide N, Kajiwara T, Terao T, Nadano S, Marui K, Okujima Y, Kokubu M, Imamura Y, Kanemitsu K, Koizumi M, Kumagi T, Hiasa Y, Hyodo I. Hino K, et al. Intern Med. 2022;61(15):2255-2261. doi: 10.2169/internalmedicine.8736-21. Epub 2022 Aug 1. Intern Med. 2022. PMID: 35908959 Free PMC article.
Association of ERBB2 Copy Number and Gene Coalterations With Trastuzumab Efficacy and Resistance in Human Epidermal Growth Factor Receptor 2-Positive Esophagogastric and Gastric Cancer.
Hino K, Nishina T, Kajiwara T, Bando H, Nakamura M, Kadowaki S, Minashi K, Yuki S, Ohta T, Hara H, Mizukami T, Moriwaki T, Ohtsubo K, Komoda M, Mitani S, Nagashima F, Kato K, Yamada T, Hasegawa H, Yamazaki K, Yoshino T, Hyodo I. Hino K, et al. JCO Precis Oncol. 2022 Aug;6:e2200135. doi: 10.1200/PO.22.00135. JCO Precis Oncol. 2022. PMID: 35952320 Free PMC article.
WJOG13219G: The Efficacy and Safety of FOLFOXIRI or Doublet plus Anti-VEGF Therapy in Previously Untreated BRAFV600E Mutant Metastatic Colorectal Cancer: A Multi-Institutional Registry-Based Study (BRACELET Study).
Shimozaki K, Hirata K, Sato T, Nakamura M, Kato K, Hirano H, Kumekawa Y, Hino K, Kawakami K, Kito Y, Matsumoto T, Kawakami T, Komoda M, Nagashima K, Sato Y, Yamazaki K, Hironaka S, Takaishi H, Hamamoto Y, Muro K. Shimozaki K, et al. Among authors: hino k. Clin Colorectal Cancer. 2022 Dec;21(4):339-346. doi: 10.1016/j.clcc.2022.08.002. Epub 2022 Aug 12. Clin Colorectal Cancer. 2022. PMID: 36117091 Free article.
Phase 1b/2 study of the liposomal formulation of eribulin (E7389-LF) in combination with nivolumab: Results from the phase 2 esophageal cancer cohort.
Oshima T, Yamamoto S, Kawakami H, Makino T, Kawazoe A, Masuishi T, Tsushima T, Hirao M, Tsuda M, Hino K, Yamamoto N, Hara H, Kaname S, Matsuoka D, Otake Y, Yasuda K, Takase T, Takashima S, Semba T, Ooki A. Oshima T, et al. Among authors: hino k. BJC Rep. 2024 Sep 4;2(1):66. doi: 10.1038/s44276-024-00066-6. BJC Rep. 2024. PMID: 39516370 Free PMC article.
Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort.
Kawazoe A, Yamamoto N, Sugimoto N, Kawakami H, Oshima T, Yamaguchi K, Hino K, Hirao M, Kurokawa Y, Kawakami T, Tsuda M, Hara H, Kaname S, Matsuoka D, Otake Y, Yasuda K, Takase T, Takashima S, Semba T, Muro K. Kawazoe A, et al. Among authors: hino k. Clin Cancer Res. 2024 Apr 1;30(7):1264-1272. doi: 10.1158/1078-0432.CCR-23-1768. Clin Cancer Res. 2024. PMID: 38295160 Free PMC article. Clinical Trial.
590 results